Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 2/2021

08.06.2021

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer

verfasst von: Arielle L. Heeke, Antoinette R. Tan

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Immunotherapy has become a mainstay of cancer treatment in many malignancies, though its application in breast cancer remains limited. Of the breast cancer subtypes, triple-negative breast cancers (TNBCs) are characterized by immune activation and infiltration and more commonly express biomarkers associated with response to immunotherapy. Checkpoint inhibitor therapy has shown promising activity in metastatic TNBC. In 2019, the US FDA granted accelerated approval of atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, in combination with nab-paclitaxel for unresectable locally advanced or metastatic PD-L1-positive TNBC, based on the results of the phase III IMpassion130 trial. In 2020, the FDA also granted accelerated approval of pembrolizumab, a PD-1 inhibitor, in combination with chemotherapy for locally recurrent unresectable and metastatic PD-L1-positive TNBC, based on results of the phase III KEYNOTE-355 trial. Additional combination strategies are being explored in the treatment of metastatic TNBC, with the goal of augmenting antitumor activity. In this review, the clinical development of checkpoint inhibitors in the treatment of metastatic TNBC will be discussed, including clinical outcomes with monotherapy and combination therapy regimens, biomarkers that may predict for benefit, and future directions in the field.
Literatur
1.
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 34(21), 2460–2467.CrossRef
2.
Nanda R, Specht J, Dees C, Berger R, Gupta S, Geva R, et al. (2016). KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple negative breast cancer. San Antonio Breast Cancer Symposium 2016. Cancer Research, 77(suppl_4): P6-10-03.
3.
Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, et al. (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for Immunotherapy of Cancer, 5, 43.
4.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. (2019). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 397–404.
5.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. (2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 405–411.CrossRef
6.
Winer EP, Lipatov O, Im SA, Goncalves A, Munoz-Couselo E, Lee KS, et al. (2021). Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. The Lancet Oncology, 22(4), 499–511.CrossRef
7.
Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney SM, Kuter I, et al. (2017). Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. AACR Annual Meeting 2017. Clinical Cancer Research, 77(suppl_13), 2986.
8.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. (2019). Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncology, 5(1), 74–82.
9.
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. (2018). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment, 167(3), 671–686.
10.
Emens LA, & Middleton G. (2015). The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunology Research, 3(5), 436–443.CrossRef
11.
Fridman WH, Zitvogel L, Sautes-Fridman C, & Kroemer G. (2017). The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 14(12), 717–734.CrossRef
12.
Galluzzi L, Buque A, Kepp O, Zitvogel L, & Kroemer G. (2017). Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology, 17(2), 97–111.CrossRef
13.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 56(5), 641–648.
14.
Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, et al. (2018). Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 168(1), 57–67.
15.
Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. (2001). Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clinical Cancer Research, 7(10), 3025–3030.
16.
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, & Djeu J Y. (2010). A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clinical Cancer Research, 16(18), 4583–4594.CrossRef
17.
Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, et al. (2013). Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology, 2(10), e27025.
18.
Li JY, Duan XF, Wang LP, Xu YJ, Huang L, Zhang TF, et al. (2014). Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. Journal of Immunology Research, 2014, 286170.PubMedPubMedCentral
19.
Jackaman C, Majewski D, Fox SA, Nowak AK, & Nelson DJ. (2012). Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunology, Immunotherapy, 61(12), 2343–2356.CrossRef
20.
Nio Y, Hirahara N, Minari Y, Iguchi C, Yamasawa K, Toga T, et al. (2000). Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. Anticancer Research, 20(5A), 3293–3299.
21.
Huang X, Cui S, & Shu Y. (2016). Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. Immunologic Research, 64(1), 160–170.CrossRef
22.
Homma Y, Taniguchi K, Nakazawa M, Matsuyama R, Mori R, Takeda K, et al. (2014). Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clinical & Translational Oncology, 16(3), 330–335.
23.
Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. (2010). 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research, 70(8), 3052–3061.
24.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. The New England Journal of Medicine, 379(22), 2108–2121.
25.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(1), 44–59.
26.
Emens LA, Adams S, Barrios CH, Dieras VC, Iwata H, Loi S, et al. (2020). IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. ESMO 2020 Virtual Congress. Annals of Oncology, 31(suppl_4), S1142–SS215.
27.
Miles DW, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios CH, et al. (2020). Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). ESMO 2020 Virtual Congress. Annals of Oncology, (suppl_4), S1142–SS215.
28.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817–1828.
29.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, et al. (2019). Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. ESMO 2019 Congress. Annals of Oncology, 30(suppl_5), v851–v934.
30.
Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, et al. (2016). In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: A comparison to bevacizumab. British Journal of Cancer, 114(11), 1212–1218.
31.
Tolaney SM, Kalinsky K, Kaklamani VG, D'Adamo DR, Aktan G, Tsai ML, et al. (2021). Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase ib/ii study. Clinical Cancer Research, online ahead of print.
32.
Nolan ESP, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, et al. (2017). Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science Translational Medicine, 9(393), eaal4922.
33.
Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, et al. (2020). Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Research and Treatment, 184(2): 265-275.
34.
Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. (2014). Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Research, 16(6), 475.
35.
Mardis ER. (2019). Neoantigens and genome instability: Impact on immunogenomic phenotypes and immunotherapy response. Genome Medicine, 11(1), 71.CrossRef
36.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. (2017). PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clinical Cancer Research, 23(14), 3711–3720.
37.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. (2015). CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunology Research, 3(11), 1257–1268.
38.
Eiermann W, Rugo HS, Diab S, Ettl J, Hurvitz SA, Goncalves A, et al. (2018). Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA). ASCO Annual Meeting 2018. Journal of Clinical Oncology, 36(suppl_15), abstract 1070.
39.
Senkus-Konefka E, Domchek SM, Im SA, Xu B, Amrstrong AC, Masuda N, et al. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. European Breast Cancer Conference 2018. European Journal of Cancer, 92(suppl_3), S19–S20.
40.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. (2018). Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. The New England Journal of Medicine, 379(8), 753–763.CrossRef
41.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. The New England Journal of Medicine, 377(6), 523–533.
42.
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. (2002). The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. Journal of Clinical Oncology, 20(9), 2310–2318.CrossRef
43.
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Marcom PK, Nanda R, et al. (2020). TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). ASCO Annual Meeting 2020. Journal of Clinical Oncology, 38(suppl_15), abstract 1002.
44.
Domagala P, Jakubowska A, Jaworska-Bieniek K, Kaczmarek K, Durda K, Kurlapska A, et al. (2015). Prevalence of Germline mutations in genes engaged in DNA damage repair by homologous recombination in patients with triple-negative and hereditary non-triple-negative breast cancers. PLoS One, 10(6), e0130393.
45.
Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, et al. (2019). Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncology, 5(8), 1132-1140.
46.
Domchek SP, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. (2019). Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). ESMO 2019 Congress. Annals of Oncology, 30(suppl_5), v475–v532.
47.
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. The Lancet Oncology, 21, 1155–1164.
48.
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. (2018). CDK4/6 Inhibition augments antitumor immunity by enhancing t-cell activation. Cancer Discovery, 8(2), 216–233.
49.
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature, 548(7668), 471–475.CrossRef
50.
Tolaney SM, Kabos P, Dickler MN, Gianni L, Jansen V, Lu Yi, et al. (2018) Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. ASCO Annual Meeting 2018. Journal of Clinical Oncology, 36(suppl_15), abstract 1059.
51.
Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, et al. (2016). MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity, 44(3), 609–621.
52.
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. (2016). RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clinical Cancer Research, 22(6), 1499–1509.
53.
Brufsky A, Kim SB, Zvirbule Z, Eniu A, Mebis J, Sohn JH, et al. (2021). A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology, 32(5), 652–660.
54.
Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, et al. (2015). Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research, 75(2), 296–305.
55.
Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, et al. (2019). Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). AACR Annual Meeting 2019. Cancer Research, 79(suppl_13), abstract CT049.
56.
Emens LA. (2012). Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Review of Anticancer Therapy, 12(12), 1597–1611.CrossRef
57.
Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. (2019). Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncology, 5(7), 1008–1019.
58.
Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. (2019). Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. Journal of Clinical Oncology, 37(30), 2730–2737.
59.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, et al. (2020). Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. European Journal of Cancer, 140, 55–62.
60.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, et al. (2020). Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist,25(4), e679–ee83.
61.
Abdel-Wahab N, Shah M, Lopez-Olivo MA, & Suarez-Almazor ME. (2018). Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Annals of Internal Medicine, 169(2), 133–134.CrossRef
62.
Woo SR, Corrales L, & Gajewski TF. (2015). The STING pathway and the T cell-inflamed tumor microenvironment. Trends in Immunology, 36(4), 250–256.CrossRef
63.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. (2014). PD-L1 expression in triple-negative breast cancer. Cancer Immunology Research, 2(4), 361–370.
64.
Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Gyorffy B, et al. (2015). Classical pathology and mutational load of breast cancer - Integration of two worlds. The Journal of Pathology. Clinical Research, 1(4), 225–238.CrossRef
65.
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486(7403), 405–409.
66.
Lynce L, Xiu J, Obeid E, Tan AR, Gatalica Z, Isaacs C, et al. (2017). Tumor mutational load in gynecological and breast cancer. ASCO-SITC Clinical Immuno-Oncology Symposium 2017. Journal of Clinical Oncology, 35(suppl 7S), abstract 44.
67.
Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. (2014). Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Annals of Oncology, 25(8), 1544–1550.
68.
Loi S, Schmid P, Aktan G, Karantza V, & Salgado R. Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) +chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial. ESMO Breast Cancer 2019. Annals of Oncology, 30(suppl_3), iii1–iii26 abstract 573.
69.
Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. (2018). Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 24(7), 986–993.CrossRef
70.
Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. (2019). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncology, 5(3), 334–342.
71.
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research, 21(7), 1688–1698.CrossRef
72.
Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, et al. (2017). Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology, 6(2), e1253654.
73.
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, et al. (2018). Immunological differences between primary and metastatic breast cancer. Annals of Oncology, 29(11), 2232–2239.
74.
Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, et al. (2020). Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal for Immunotherapy of Cancer, 8(2), e001558.
Metadaten
Titel
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
verfasst von
Arielle L. Heeke
Antoinette R. Tan
Publikationsdatum
08.06.2021
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2/2021
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-021-09972-4

Weitere Artikel der Ausgabe 2/2021

Cancer and Metastasis Reviews 2/2021 Zur Ausgabe

Clinical

Gastrointestinal stromal tumor: a review of current and emerging therapies

ReviewPaper

Emerging roles for myeloid immune cells in bone metastasis

ReviewPaper

Informing the new developments and future of cancer immunotherapy

Non-Thematic Review

Rethinking the biology of metastatic melanoma: a holistic approach

ReviewPaper

MHC heterogeneity and response of metastases to immunotherapy

ReviewPaper

The role of tumor heterogeneity in immune-tumor interactions

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise